Insilico Biotechnology AG develops and delivers predictive digital twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Groundbreaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilco’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico digital twins for cell line development, media design, and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.